Immune system
Your body's frontline antibiotic peptide — it kills bacteria, disarms their toxins, and has reached mid-stage human trials for stubborn wound healing.
Start here
LL-37 is an antimicrobial peptide your own immune cells make — the human form of a defense molecule called cathelicidin. It kills bacteria by piercing their membranes, neutralizes bacterial toxins, and recruits immune cells to infection sites. A version called Ropocamptide has reached Phase II human trials for hard-to-heal leg ulcers, where it sped up wound healing; LL-37 itself remains a research compound, not an approved drug.
LL-37 is the active form of cathelicidin, an antimicrobial peptide your immune cells produce to kill bacteria, viruses, and fungi while also reducing inflammation and promoting wound healing.
LL-37 (also known as the last 37 amino acids of hCAP-18) is a positively charged, spiral-shaped (α-helical) peptide of 37 amino acids. It is cut from its precursor protein hCAP18 by neutrophil elastase and cathepsin G (protein-cutting enzymes from white blood cells). LL-37 kills germs in several ways: it forms membrane-spanning pores (holes) that break open their outer skin, it soaks up lipopolysaccharides and lipoteichoic acids (toxins from bacterial walls), it attacks bacterial nucleic acids (DNA and RNA) inside the cell, and it triggers autophagy (the cell's self-cleaning process). Beyond killing germs, LL-37 tunes the immune system through TLR9 signaling (a germ-sensing pathway), draws immune cells to a spot (chemotaxis) by activating formyl peptide receptor-like 1 (FPRL-1, also called the lipoxin A4 receptor), boosts angiogenesis (new blood vessel growth) and wound healing, and holds back excessive inflammation by raising IL-10 (an anti-inflammatory signal).
Evidence check
Some human studies
It has been tested in people, but only in small or early-stage studies. Promising, but not yet proven the way an approved medicine is.
Every numbered marker on this page links to one of the 5 sources at the bottom.
Wound Healing
Clinical trials show this peptide heals stubborn wounds six times faster than placebo by boosting new blood vessel growth and tissue repair.
Fighting Infections
Works like a natural antibiotic in your body, punching holes in harmful bacteria including drug-resistant strains that normal antibiotics can't kill.
Immune Boost
Calls your immune cells to action like a chemical alarm, helping your body mount a stronger defense against bacteria, fungi, and viruses.
The most-asked question
The research-reported range is 1.6 mg/mL, once daily. Studies used different doses for different situations — find yours:
Hard-to-heal venous leg ulcers, Chronic wound healing
0.5 mg/mL gel
Lowest dose in the LL-37 (ropocamptide) Phase I/IIa venous leg-ulcer trial and the most effective: ~6-fold faster healing and ~68% ulcer-area reduction vs placebo, applied to the wound twice weekly 4.
Hard-to-heal venous leg ulcers, Chronic wound healing
1.6 mg/mL gel
Mid dose in the same trial; ~3-fold improvement and ~50% area reduction vs placebo. The highest tested concentration (3.2 mg/mL) showed no benefit over placebo, so dose escalation above this is not supported 4.
The ceiling: 1.6 (as determined by your healthcare provider based on individual response and tolerance)
Reconstitution, in plain words
Peptides usually arrive as a freeze-dried powder in a small vial. “Reconstitution” just means adding sterile water back in so you can measure a dose. Here's how it works for LL-37:
LL-37 comes in pre-measured doses or forms. Follow the exact dosing instructions on your prescription label. No reconstitution or mixing is typically required for this formulation.
Use LL-37 exactly as prescribed. Each unit contains the labeled amount. Your healthcare provider will determine the appropriate dose based on your individual needs and response.
Three quick questions — your vial, your water, your dose — and it tells you the exact syringe mark. “Find dose amount” is preloaded with LL-37's recorded schedule.
Injection sites & technique
LL-37 is applied to the wound or skin (to help wounds heal). No injection is needed.
Timing
Apply LL-37 to clean, dry skin. For best results, use consistently at the same time(s) each day. Evening application is often preferred to allow overnight absorption, unless otherwise directed.
As a topical product, LL-37 is not affected by food intake. Apply to clean skin and allow adequate absorption time before covering the area.
LL-37 should be used as directed by your healthcare provider. If combining with other medications or supplements, discuss potential interactions with your provider. Avoid combining with compounds that have overlapping mechanisms unless specifically guided by a medical professional.
The honest list
These show up most often. They usually fade as your body adjusts.
Mild redness, warmth, or irritation at the wound application site. This is the most frequently reported adverse effect in clinical trials 4 and reflects the peptide's interaction with wound-bed tissues.
What to do Generally self-limiting. If irritation is significant, reduce application frequency to every other day. Ensure wound is gently cleansed before application.
Brief stinging or burning sensation upon application to open wound surfaces, typically lasting seconds to minutes.
What to do Allow reconstituted solution to reach room temperature before application. Sensation typically diminishes with subsequent applications as wound healing progresses.
Redness in the skin around the treated wound, reflecting local immune activation and extra blood flow from LL-37 helping grow new blood vessels.
What to do Usually indicates active healing response. Monitor for signs of infection versus expected inflammatory healing. Should remain localized and non-spreading.
Temporary increase in wound fluid production during initial treatment phase as antimicrobial and pro-healing mechanisms activate.
What to do Use appropriate absorbent wound dressings. Typically normalizes within 1-2 weeks as healing progresses and bacterial bioburden is reduced.
Worth knowing about, but most people never see these.
Local allergic reaction around the application site in sensitized people, with itching, hives, or contact dermatitis (irritated, inflamed skin).
What to do Discontinue LL-37 application. Apply topical corticosteroid to affected periwound skin. Perform patch test before resuming. Consider alternative wound care.
Rare, but if any of these happen, stop and contact a medical professional.
LL-37 demonstrates concentration-dependent hemolysis of human red blood cells at elevated systemic (affecting the whole body) concentrations. This limits parenteral (IV/IM) dosing potential but is not observed with topical wound application at therapeutic doses used in clinical trials.
What to do Topical application avoids systemic (affecting the whole body) hemolysis risk. For any research involving parenteral administration, monitor hemoglobin and hematocrit. Dose-limiting toxicity for systemic routes.
Week by week
Is it right for you?
LL-37 should only be started, adjusted, or discontinued under medical supervision. This information is for educational purposes only and does not replace professional medical advice. Never stop a prescribed treatment without consulting your healthcare provider first, as abrupt discontinuation may have consequences.
Use with caution—discuss with your healthcare provider.
Use with caution—discuss with your healthcare provider.
Use with caution—discuss with your healthcare provider.
May be used together under medical guidance.
May be used together under medical guidance.
May be used together under medical guidance.
Generally safe to take alongside LL-37. Space doses apart if taking oral formulations to ensure optimal absorption.
Helpful if experiencing any GI side effects that could lead to dehydration. Safe to combine.
LL-37 is particularly well-suited for individuals focused on treatment of chronic non-healing wounds including venous leg ulcers and diabetic ulcers. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach 4.
LL-37 is particularly well-suited for individuals focused on immune defense against antibiotic-resistant bacterial infections (mrsa, pseudomonas). Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach 35.
LL-37 is particularly well-suited for individuals focused on anti-biofilm strategies for chronic wound infections and medical device-associated infections. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach 5.
LL-37 is particularly well-suited for individuals focused on boosting innate immune defense in immunocompromised or aging individuals. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach 2.
LL-37 is an endogenous (made naturally by your body) cathelicidin antimicrobial peptide (a germ-fighting protein the body makes itself) produced naturally by immune cells and the cells lining skin and organs, 2 so it is inherently biocompatible and has low toxicity at natural levels. Synthetic LL-37 shows excellent safety in in vitro (in lab dishes, not living bodies) immune tests (assays) and animal models, with no liver, kidney, or DNA toxicity at relevant doses. At high concentrations, its positively charged, membrane-disrupting structure can burst red blood cells (hemolysis) and damage cell membranes, but therapeutic doses are far below those levels. Injection site reactions are minimal in research use.
LL-37 safety derives from extensive basic research in immunology and dermatology journals (Nature Immunology, Journal of Immunology) demonstrating antimicrobial activity, wound healing promotion, and immune modulation 2 without systemic (affecting the whole body) toxicity. Human clinical data are limited—most applications remain in vitro (in lab dishes, not living bodies) or preclinical (animal or lab studies, not human trials). Phase 1 safety and pharmacokinetics (how the body absorbs and clears a compound) data suggest good tolerability, but Phase 2+ efficacy trials in infectious disease and skin conditions are ongoing. The peptide is generally recognized as safe for topical and research applications.
Keeping it good
Store LL-37 in the refrigerator at 36-46°F (2-8°C) in its original packaging. Protect from light and moisture. Do not freeze. Check the expiration date before use. Some formulations may be stored at room temperature for limited periods—check your specific product labeling.
Once reconstituted, LL-37 should be kept refrigerated at 36-46°F (2-8°C) and used within the timeframe specified on your product labeling (typically 14-28 days). Label the vial with the reconstitution date. Do not use if the solution appears cloudy, discolored, or contains particles.
Not our opinion — the published record
2000
DNA ligase III's zinc finger (a zinc-holding part of the protein) lets it find and repair DNA breaks at spots with clustered damage. This matters most for recovering from radiation injury.
Taylor RM, Whitehouse CJ, Caldecott KW
2006
Research (2006) shows LL-37 is a strong germ killer that works against a wide range of disease-causing microbes.
Dürr UH, Sudheendra US, Ramamoorthy A
1998
Research (1996) shows LL-37 is a strong germ killer that works against a wide range of disease-causing microbes.
Turner J, Cho Y, Dinh NN, et al.
2014
Clinical trial (2014) gives evidence that LL-37 works as a treatment.
Grönberg A, Mahlapuu M, Ståhle M, Whately-Smith C, Rollman O
2014
Antimicrob Agents Chemother 2014;58(8):4411-9 (PMID 24841266). Synthetic LL-37-derived peptides P60.4Ac and P10 killed MRSA (a drug-resistant staph bacterium) more efficiently than LL-37. They also broke up biofilm (slimy germ colonies) well, were non-toxic to human epidermal models (lab-grown human skin), and wiped out MRSA, including a mupirocin-resistant strain (resistant to a common skin antibiotic), from thermally wounded human skin equivalents (lab-grown human skin with burn wounds).
Haisma EM, de Breij A, Chan H, van Dissel JT, Drijfhout JW, Hiemstra PS, El Ghalbzouri A, Nibbering PH
If this isn't the right fit
Your questions
LL-37 is the only cathelicidin antimicrobial peptide found in humans. The name derives from its first two amino acids (both Leucine, abbreviated 'L') and its total length of 37 amino acids. It is cleaved from the C-terminus of the 18 kDa precursor protein hCAP-18 (human cationic antimicrobial protein) by proteinase 3 in neutrophils and by kallikreins in skin. Stored in neutrophil specific granules and secreted by epithelial (surface-lining tissue) cells, LL-37 is a first-line innate immune defense peptide expressed by the CAMP gene on chromosome 3.
LL-37 (under the pharmaceutical name Ropocamptide, developed by Promore Pharma in Sweden) completed a Phase I/IIa clinical trial with 34 patients with hard-to-heal venous leg ulcers. The 0.5 mg/mL topical formulation showed a 6-fold greater healing rate than placebo over 4 weeks. A larger 148-patient Phase IIb trial has also been completed. LL-37 helps wounds heal through a mix of germ-killing, biofilm-fighting, new-blood-vessel-growing (angiogenic), and keratinocyte (skin cell) migration-promoting actions.
Unlike conventional antibiotics that target specific molecular pathways (which bacteria can evolve resistance to), LL-37 kills bacteria through physical membrane disruption — its cationic charge attracts it to anionic bacterial membranes, and its alpha-helical structure creates pores that rapidly lyse the cell. This physical mechanism makes resistance development much more difficult. Additionally, LL-37 disrupts bacterial biofilms, which are the primary reason chronic wound infections resist antibiotic treatment, and it recruits immune cells to clear remaining bacteria.
Vitamin D directly switches on the CAMP gene, which makes hCAP-18 (the precursor protein of LL-37). The vitamin D receptor (VDR) binds to a vitamin D response element (a DNA switch) in the CAMP promoter, increasing LL-37 production. This is a key reason vitamin D supplementation supports immune function: it boosts the body's production of its main antimicrobial peptide. Vitamin D deficiency is linked to lower LL-37 levels and greater susceptibility to infection.
LL-37 demonstrates concentration-dependent hemolytic activity — at higher systemic (affecting the whole body) concentrations needed for parenteral antimicrobial therapy, the peptide's membrane-disrupting mechanism also affects human red blood cells. Additionally, serum proteins partially bind and inactivate the peptide, and its half-life (how long it stays active in your body) in circulation is short due to rapid proteolytic degradation. This is why clinical development has focused on topical wound application, where high local concentrations can be achieved without systemic hemolysis concerns.
LL-37 takes a very different approach. Rather than hitting a single bacterial pathway, it physically breaks up bacterial membranes, neutralizes endotoxin (a toxin from bacterial walls), destroys biofilms, recruits immune cells, and helps wounds heal by growing new blood vessels (angiogenesis (the growth of new blood vessels)) and moving skin cells into the wound (keratinocyte migration). Conventional antibiotics kill bacteria but do not promote healing, cannot penetrate biofilms effectively, and face growing resistance. LL-37 addresses all these limits while staying effective against antibiotic-resistant strains including MRSA (a resistant staph) and multi-drug resistant Pseudomonas.
5 sources
Every numbered marker on this page points to one of these. Same sources, same numbering as the LL-37 research profile on Peptide Initiative.
Want the deep science?
Every claim on this page traces back to the research database behind Peptide Initiative — studies, citations, clinical trial data, and the technical detail we deliberately left out here.
Open the research profileThis guide is education, not medical advice. LL-37 is a research compound that is not FDA-approved for human use. Talk to a clinician before taking anything.
PeptideGeek